(Q34354529)

English

Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

J Sehouli

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

A Reinthaller

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

C Marth

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

D Reimer

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

T Reimer

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

W Stummvoll

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

L Angleitner-Boubenizek

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

B Brandt

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

R Chekerov

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

16 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

111

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1519-1525

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Molecular approaches to personalizing management of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Early diagnosis of ovarian carcinoma: is a solution in sight?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Peritoneal-based malignancies and their treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Current and future options in the treatment of malignant ascites in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Challenges for chemotherapy in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Frequent EpCam protein expression in human carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4200087

6 July 2018

Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.443

21 January 2018

Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.443

21 January 2018

Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25225907

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25225907

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/25225907

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25225907

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing

1 reference

https://pubmed.ncbi.nlm.nih.gov/25225907

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2014.443

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34354529&oldid=2196541567"